Here's Why Shares in Danaher Got Boosted Higher Today

Shares in biotechnology, life sciences, and diagnostics company Danaher (DHR +0.06%) rose by as much as 12.9% in early morning trading today. The move follows a well-received third-quarter earnings report, which saw the company beat its own and the market's expectations.

What happened in Danaher's third quarter

Having forecast core revenue growth in the low-single-digit range and an adjusted operating profit margin of 25.5% for the third quarter on its second-quarter earnings call, management was pleased to announce core revenue growth of 3% and an adjusted operating profit margin of 27.9% for the third quarter.

Expand

NYSE: DHR

Danaher

Today's Change

(0.06%) $12.38

Current Price

$220.77

Key Data Points

Market Cap

$149B

Day's Range

$220.73 - $234.99

52wk Range

$171.00 - $269.24

Volume

11M

Avg Vol

4.3M

Gross Margin

61.52%

Dividend Yield

0.01%

Management put the outperformance down to "DBS-driven execution paired with continued momentum in our bioprocessing business and better-than-anticipated respiratory revenue at Cepheid." DBS refers to the Danaher Business System (a management system emphasizing continuous improvement). Danaher's bioprocessing business continues on a strong growth path, driven by increasing production and research into biologics, notably monoclonal antibodies.

As for the better-than-expected growth at Cepheid (its diagnostics segment), CEO Rainer Blair said, "Customers began purchasing earlier than typical in preparation for the upcoming respiratory season," in other words, Danaher benefited from a pull-forward in revenue driven by the flu season.

What it means for investors

While a good set of results is always positive, the market may have overreacted to this news. Management's preliminary guidance for 2026 calls for core revenue growth of 3% to 6% (a pretty wide range at the best of times) and no more than high-single-digit earnings growth. That encompasses what the market was expecting before these earnings, with biotechnology offsetting modest growth in life sciences, and uncertainty around the diagnostics segment's exposure to China. That's fair enough, but with the stock trading at almost 29 times the estimated 2025 earnings, it might not be enough to take the stock significantly higher from here.